Boston Scientific

BSX

市值 US$643億

Boston Scientific (BSX) closed at $44.14 in the latest trading session, marking a +2.65% move from the prior day.

Boston Scientific (BSX) reached $42.73 at the closing of the latest trading day, reflecting a +1.64% change compared to its last close.

Boston Scientific (BSX) concluded the recent trading session at $42.04, signifying a +1.11% move from its prior day's close.

Recently, Zacks.com users have been paying close attention to Boston Scientific (BSX). This makes it worthwhile to examine what the stock has in store.

New operating structure designed to increase efficiency and support continued growth MARLBOROUGH, Mass., Oct. 7, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the appointment of Joseph M.

In the latest trading session, Boston Scientific (BSX) closed at $42.6, marking a -1.46% move from the previous day.

Boston Scientific released the full $8 million holdback on schedule and with no claims Escrow release is the third funding catalyst Elutia has delivered in 2026, following the August closings of its Avenue Capital loan facility and SimpliDerm® divestiture The Company is now fully funded through the first year of the expected NXT-41x launch and into 2029 GAITHERSBURG, Md., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced it has received the full $8 million held in escrow in connection with the sale of its BioEnvelope business to Boston Scientific Corporation (NYSE: BSX).

BSX's MedSurg segment supports growth, with Endoscopy and Neuromodulation gains offsetting Urology challenges and portfolio gaps.

Boston Scientific stock slumped 55% over 12 months, driven by weakness in electrophysiology and WATCHMAN, which comprise only 26% of 2025 sales. Despite headline challenges, 74% of BSX's business grew at a robust 7% in Q2 2026, indicating underlying strength. Management cut 2026 guidance three times, with organic growth lowered to 5-6% and EPS guidance trimmed to $3.28-$3.32, amplifying investor pessimism.

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.